Search

Introduction: Iodine uptake and the effect of radioiodine treatment of nontoxic goiter were investigated after the introduction of iodine to salt., Materials and Methods: A retrospective study was done of 61 patients (48 women and 13 men with a median age of 56 (range 28-78)) with nontoxic goiter, examined by 24-hour radioiodine uptake. 42 of the patients were treated with radioiodine (median 600 MBq, range 200-600 MBq). The results were compared with those from a study done 10 years ago in the same area., Results: Iodine uptake decreased significantly, from 40% (range 16-67%) in 1981-1993 to 25% (range 13-62%) in 2001-2003. 38 of the 42 patients were examined, and of these 34 (90%) had benefited from the treatment (53% of the 38 patients showed a complete effect) as estimated by the patient and the physician, based on the patient's original symptoms and the physician's clinical judgement. Four patients developed hypothyroidism, one radiation-induced thyroiditis and three Graves" disease., Discussion: Iodine uptake is significantly lowered after the addition of iodine to salt. Radioiodine therapy of nontoxic goiter will continue to be effective.

The aim of the study was to evaluate differences in the use of radioactive iodine in the treatment of benign thyroid disease in Denmark. A questionnaire was distributed to all departments in Denmark which administer radioiodine in the treatment of benign thyroid disease (n = 20). Radioiodine is used for patients with toxic nodular goitre and for patients with relapse of toxic diffuse goitre. Four departments did not use radioiodine for volume reduction in non-toxic goitre. Patient informations included very different recommendations regarding cautions in relation to radioiodine treatment. Radioiodine is widely used in the treatment of benign thyroid disease. We recommend a national standardization of the cautions in relation to radioiodine treatment.

Traditional treatment modalities of diffuse nontoxic goitre are thyroid hormone suppression or surgery. When treating nodular nontoxic goitre with 131I treatment, a reduction in thyroid volume to about 50% is seen. In the present study we evaluated the effect of 131I treatment in 21 patients treated for a diffuse nontoxic goitre and followed by evaluation of thyroid volume measured by ultrasound. Thyroid volume declined in all patients from median of 66 ml (range 27-160 ml) to 21 ml (9-108 ml) over a year, a reduction of 62%. Three patients developed hypothyroidism in the follow-up period (14%), one of these had a temporary hyperthyroid fase. In conclusion, 131I treatment of diffuse nontoxic goitre reduces thyroid volume by approximately 60% within 12 months. Hypothyroidism developed in 14% during a limited follow-up period.